52
Participants
Start Date
January 25, 2023
Primary Completion Date
June 17, 2024
Study Completion Date
June 17, 2024
CHF10067 starting dose -- 1000mg (Cohort A)
Intravenous administration of a starting dose of the monoclonal antibody
CHF10067 intermediate dose -- 2000mg (Cohort B)
Intravenous administration of an intermediate dose of the monoclonal antibody
CHF10067 high dose -- 3000mg (Cohort C)
Intravenous administration of a high dose of the monoclonal antibody
Placebo
Intravenous administration of a physiological solution as placebo
PHI University Clinic of Pulmonology and Allergology, Skopje
"Medical Center of Limited Liability Company Arensia Exploratory Medicine, department of Clinical Trials", Kyiv
Queen Elizabeth Hospital - NIHR Birmingham Clinical Research Facility - University Hospitals Birmingham NHS Foundation Trust, Birmingham
Royal Papworth Hospital NHSFT - Cambridge Biomedical Campus, Cambridge
University of Dundee, NHS Tayside - Ninewells Hospital & Medical School, Dundee
Interstitial Lung Disease Research - NHS Lothian - Royal Infirmary of Edinburgh,, Edinburgh
Liverpool Clinical Research Facility - Liverpool University Hospital Foundation Trust, Liverpool
Medicines Evaluation Unit - The Langley Building, Manchester
University Hospital Southampton - Department of Respiratory Medicine, Southampton
Chiesi Farmaceutici S.p.A.
INDUSTRY